{"url_path":"/sec/tbph/8-k/2026-06-23/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-076857-index.html","accession_number":"0001104659-26-076857","cik":"0001583107","ticker":"TBPH","issuer_name":"Theravance Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-076857-index.html","primary_entity_key":"0001583107","primary_entity_name":"Theravance Biopharma, Inc."},"word_count":315,"has_tables":true,"body_markdown":"**Item 5.02**\n**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\n(b) and (e)\n\n \n\nOn June 19, 2026, Theravance Biopharma Ireland Limited, a subsidiary\nof the Registrant Theravance Biopharma, Inc. (together, the “Company”), entered into a compromise agreement (the “Compromise\nAgreement”) with Áine Miller, the Company’s Senior Vice President, Development and Head of Ireland Office, pursuant\nto which Dr. Miller’s employment with the Company will terminate (the “Termination”) on November 15, 2026 (the “Termination\nDate”) in connection with the restructuring announced by the Company in March 2026 (the “Restructuring”). The Compromise\nAgreement provided for compensation and other terms consistent with the Employment Agreement entered into between Dr. Miller and the Company\non February 10, 2020, as amended on February 8, 2026. In connection with the Termination, the Company also entered into a pension side\nletter (the “Side Letter”) with Dr. Miller, pursuant to which the Company will make a special contribution for the benefit\nof Dr. Miller in the amount of $250,000 within 30 days of the Termination Date.\n\n \n\nOn June 19, 2026, Dr. Miller received a grant of 18,750 restricted\nshare units. The grant was made in connection with Dr. Miller’s continued service to the Company through the Termination Date.\n\n \n\nThe foregoing descriptions of the Compromise Agreement and Side Letter\ndo not purport to be complete and are qualified in their entirety by reference to the full text of such documents, copies of which the\nCompany intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2026.\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**THERAVANCE BIOPHARMA, INC.**\n\n \n \n\nDate: June 23, 2026\nBy:\n/s/ Rick E Winningham\n\n \n \nRick E Winningham\n\n \n \nChief Executive Officer"}